Bristol Myers Squibb reported annual gross revenue of $48.3 billion, marking a 12% increase year-over-year driven by strong sales of oncology and cardiovascular therapies. Despite top-line strength, the company recorded a net loss of $8.95 billion, reflecting a $10 billion charge related to the recent acquisition integration and restructuring. Excluding one-time items, adjusted net income reached $6.2 billion, with earnings per share of $2.96, underscoring solid underlying cash flow generation in core franchises such as Eliquis and Opdivo.

In late-stage trials of Camzyos for adolescent obstructive hypertrophic cardiomyopathy, Bristol Myers Squibb reported a 35% reduction in left ventricular outflow tract gradient compared with placebo and a favorable safety profile consistent with adult data. This result expands the company’s cardiovascular pipeline, positioning Camzyos as a potential growth driver following recent setbacks in fibrosis and immunology. Regulatory filings are on track for Q4 submission, with peak annual sales estimated at $1.2 billion in the U.S. and Europe.

On the recommendation front, 20 analysts covering Bristol Myers Squibb maintain a consensus rating of Moderate Buy, with a median price target implying flat to modest upside from current levels. Institutional ownership stands at 76.4%, reflecting confidence from pension funds and mutual managers, while insider holdings remain low at 0.1%. The stock’s beta of 0.29 highlights defensive characteristics, appealing to income-oriented investors amid broader market volatility.